5 Key Takeaways

• 1

  Cystic fibrosis affects approximately 162,000 individuals globally, leading to recurrent infections and lung damage due to thick mucus.

• 2

  CFTR modulator therapies have improved outcomes for many with cystic fibrosis but have also complicated infection detection and monitoring.

• 3

  Reduced sputum production in patients on CFTR modulators limits the effectiveness of traditional sputum culture for identifying respiratory pathogens.

• 4

  There is a pressing need for innovative diagnostic approaches that utilize alternative sample types and provide timely, actionable information.

• 5

  The CF AMR Syndicate facilitates the development of new diagnostics by connecting innovators with resources and expertise to address unmet needs.